ENSCHealthcare · Biotechnology

ENSC Stock Forecast: Ensysce Biosciences, Inc. Price Predictions for 2026-2027

Last close, 13 Oct 2026

$0.57

+2.97% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 13 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$10.8M

Ticker Nerd rank

32 / 100

Median analyst target

$8.25

Analysts covering

Revenue$0.0

Operating income−$2.6M

Net income−$2.6M

Free cash flow−$2.0M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+33.1%

+17.6%

YTD

−37.8%

−75.3%

From 52W high

−77.7%

From 52W low

+128.1%

$0.25

$2.57

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

ENSC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ensysce Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Oct 2026

32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Revisions

Issuance

Value

Growth

Momentum

Volatility

Quality

Size (91): Smaller than most of the companies we track.

Quality (6): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ENSC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENSC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
25 Sept 2023	HC Wainwright & Co.	Maintains	Buy	$9.00 → $7.00
3 July 2023	HC Wainwright & Co.	Initiates	Buy	—
17 Nov 2022	Lake Street	Maintains	Buy	$80 → $8.00
30 Nov 2021	Lake Street	Initiates	Buy	$4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ENSC appears on the weeks it earns a place.

Performance

ENSC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Oct 2026, Ensysce Biosciences, Inc. returned −75.3% against +18.6% for the S&P 500, dividends included.

ENSC vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ENSC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Ensysce Biosciences, Inc. (ENSC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.0×
Price / sales: 2.4×
Price / book: −6.5×
EV / EBITDA: −1.0×

Growth & margins

Revenue growth (YoY): −15.1%
Earnings growth (YoY): —
Gross margin: —
Operating margin: −221.3%
Net margin: −280.5%

Returns & dividend

Return on equity: −1295.1%
Return on assets: −185.5%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ensysce Biosciences, Inc. (ENSC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Ensysce Biosciences, Inc. has a market value of $10.8M and an enterprise value of $10.0M.
Revenue in the twelve months to 30 June 2026: $0.0. The latest quarter shrank 15.1% year on year.
Net income over the same four quarters: −$12.6M.
Diluted earnings per share, trailing twelve months: $−2.76.
Free cash flow in the twelve months to 30 June 2026: −$9.0M.
Shares outstanding: 15.4M.
Trailing P/E: 0.0×; forward P/E: −11.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Ensysce Biosciences, Inc. employs 8 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

ENSC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
ENSCEnsysce Biosciences, Inc.	$10.8M	32
ACTUActuate Therapeutics, Inc.	$11.2M	34
KPRXKiora Pharmaceuticals, Inc.	$10.9M	76
PHIOPhio Pharmaceuticals Corp.	$10.9M	15
AEONAEON Biopharma, Inc.	$11.5M	51
TPSTTempest Therapeutics, Inc.	$11.5M	45
INABIN8bio, Inc.	$11.5M	56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ensysce Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ENSC news & analysis

Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA

Accesswire · 24 Sept 2026positive

Ensysce Biosciences announced it submitted the protocol (CYBIO_001) for a Phase 2a clinical study of CY200 to the UK Medicines and Healthcare products Regulatory Agency (MHRA). The randomised, double-blind, placebo-controlled proof-of-concept study is designed to evaluate CY200's efficacy, safety, and tolerability in adults with Complex Regional Pain Syndrome Type 1.

Why it matters — This submission marks a key regulatory step toward initiating the first Phase 2 study of the newly acquired CY200 candidate, advancing Ensysce's CRPS-focused neuroplastogenic pipeline.

Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation

Accesswire · 15 Sept 2026positive

Ensysce Biosciences hosted a symposium at PainWeek 2026 attended by more than 320 pain management professionals, advancing its CRPS program. The company also contributed to an FDA hearing on psychedelic drug regulation.

Why it matters — The symposium attendance demonstrates growing engagement with pain management professionals for Ensysce's CRPS-focused neuroplastogenic pipeline, while its participation in the FDA hearing positions the company within broader regulatory discussions relevant to its therapy area.

Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

Accesswire · 14 Sept 2026positive

Ensysce Biosciences announced that Richard Langford, Chief Medical Officer of Cy Biopharma, has been selected to present in person at an FDA public hearing on potential future therapeutic use of psychedelic drugs, taking place September 14, 2026 at the FDA's White Oak Campus in Maryland. Dr. Langford is among a limited group of stakeholders invited to provide comments during the afternoon session on considerations for access and best practices for data collection and standardization.

Why it matters — The selection of Dr. Langford to speak at a major FDA hearing highlights Ensysce's engagement with regulators and its visibility as a clinical-stage biotech developing novel neuroplastogenic therapies.

Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation

Accesswire · 2 Sept 2026neutral

Ensysce Biosciences announced its participation in upcoming investor conferences and industry events, including the 2026 Cantor Global Healthcare Conference to be held September 9-12 at the Waldorf Astoria in New York City. The clinical-stage biotech company is developing novel neuroplastogenic therapies with an initial focus on CRPS.

Why it matters — ENSC watchers would care because the company's participation in these conferences may provide opportunities for investor exposure and updates on its clinical-stage pipeline focused on CRPS.

Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study

Accesswire · 31 Aug 2026positive

Ensysce Biosciences announced completion of enrollment in the final stage of its PF614-MPAR-102 clinical study, which evaluated its MPAR overdose-protection technology. The study is the second fully enrolled study for the company's Breakthrough Therapy-Designated, first-in-class opioid designed to protect against oral overdose.

Why it matters — This milestone advances the clinical development of a first-in-class opioid candidate with abuse-resistance and overdose-protection technology, which is central to Ensysce's pipeline.

FAQ

Frequently asked questions about ENSC stock

How does Ticker Nerd's model rank ENSC?

As at 13 Oct 2026, Ensysce Biosciences, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).

What is the ENSC stock forecast for 2030?

No analyst covering Ensysce Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENSC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8.25 to $8.25 over the next 12 months.

How has ENSC stock performed over the past year?

Ensysce Biosciences, Inc. returned -75.3% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ensysce Biosciences, Inc. do?

What is the latest news on ENSC?

The most recent item we track (Accesswire, 24 Sept 2026): "Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA". Ensysce Biosciences announced it submitted the protocol (CYBIO_001) for a Phase 2a clinical study of CY200 to the UK Medicines and Healthcare products Regulatory Agency (MHRA). The randomised, double-blind, placebo-controlled proof-of-concept study is designed to evaluate CY200's efficacy, safety, and tolerability in adults with Complex Regional Pain Syndrome Type 1.

Company

About Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. Common Stock represents ownership in Ensysce Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing prescription therapies for severe pain and central nervous system conditions. The company’s current work centers on proprietary drug-delivery and abuse-deterrence platforms, including Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), which are designed to improve how certain medications are activated and to reduce the risks of misuse, abuse, and overdose. Its pipeline includes candidates for pain management, opioid protection, and attention deficit hyperactivity disorder, reflecting a focus on controlled pharmaceutical innovation rather than broad commercial medicines. Based in La Jolla, California, Ensysce Biosciences operates in the biotechnology and pharmaceuticals segment of the healthcare market, where it contributes to research-driven solutions aimed at safer treatment options for patients and clinicians.

CEO Dr. D. Lynn Kirkpatrick Ph.D. · 8 employees · United States · https://www.ensysce.com